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Abstract
Background: Use of antipsychotic (AP) medications is high and often inappropriate among institutionalized
populations. Little is known about the correlates of new AP drug use following admission to long-term care
(LTC) settings. This study investigated the frequency and correlates of new AP drug use among newly admitted LTC
residents.
Methods: This longitudinal, retrospective study used data from the interRAI - Nursing Home Minimum Data Set
version 2.0 (MDS 2.0) instrument. Data about demographic, clinical and social characteristics, and medication use,
were collected in Ontario, Canada, from 2003–2011 by trained nurses. Residents with complete admission and 3–6
month follow-up data were included (N = 47,768). Multivariate logistic regression analyses, stratified by gender,
explored correlates of new AP drug use upon admission to LTC.
Results: New AP drug users comprised 7 % of the final cohort. Severe cognitive impairment, dementia, and motor
agitation were significantly associated with new AP drug use among both sexes. Additionally, behavioural
problems, conflicts with staff and reduced social engagement were strong correlates of new AP drug use.
Conclusions: Social factors were as strongly associated with new AP drug use after LTC admission as clinical
factors. Strategies to prevent the potential misuse of AP drugs upon LTC admission should consider the social
determinants of such prescribing.
Keywords: Long-term care, Mental health, Antipsychotic medications, Risk factors, InterRAI assessment instruments
Background
Despite being approved for indications such as schizo-
phrenia and bipolar disorder, antipsychotic (AP) drugs
are prescribed off-label for numerous clinical condi-
tions and disorders and are commonly used to treat
the behavioural and psychiatric symptoms of dementia
(BPSD) [1–3]. Dementia is a progressive, irreversible
clinical syndrome, affecting 35.6 million people world-
wide [4]. It is characterized by widespread decline in
intellectual functions such as memory, communication
skills, performing day-to-day activities, reasoning, and
changes in social behaviour [5]. More than 80 % of
nursing home residents with dementia develop BPSD
[6, 7]. BPSD symptoms are characterized by agitation,
aggression, restlessness, wandering, shouting, repeti-
tive vocalizations, sleep disturbance, depression and
psychosis [8].
AP drugs are commonly prescribed to reduce BPSD
despite the lack of evidence about their efficacy, high pla-
cebo responses and serious adverse events [9–11]. There
is growing international concern about the misuse of psy-
chotropic medications, including AP drugs, as chemical
restraints, particularly in institutionalized populations
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[12–14]. Estimates of AP drug use in nursing home envi-
ronments range from 20 to 44 % [15–18]. In European
nursing homes, this rate was 33 % among residents with
dementia [19]. More worryingly, studies have shown that
as much as 80 % of this use is among residents without a
diagnosis of severe mental illness [15, 16, 18].
Use of atypical AP drugs in patients with dementia
can lead to acute and sub-acute side effects, in particular
sedation, postural hypotension, and falls, especially at
higher doses. Conventional AP drugs can frequently
cause serious adverse effects such as extrapyramidal syn-
drome and tardive dyskinesia [1]. In 2005, both the U.S.
Food and Drug Administration (FDA) and Health
Canada issued black-box warnings for atypical AP drugs
due to increased risk of mortality and cerebrovascular
events among patients with dementia [20, 21]. Based on
newer evidence, the FDA extended this warning to include
conventional AP drugs in 2008 [22]. Similar European rec-
ommendations were released by the European Medicines
Agency (EMA) in 2008 [23]. The effectiveness of these
warnings has been studied. In North America, overall pre-
scription rates of AP drugs to individuals with dementia
declined, while overall absolute rates of AP drugs contin-
ued to increase [24, 25].
The transition from community to long-term care
(LTC) facilities is usually stressful. Only a small proportion
of AP drug use upon LTC admission appears to be con-
tinuation of prior AP drug use [26]. Thus, it is possible
that behavioural changes in response to such transitions
could trigger new AP drug prescriptions. Alternately,
BPSD could itself be a trigger for institutionalization.
Nonetheless, LTC admission and the change in environ-
ment could be risk factors for the new (and sometimes ex-
cessive) use of AP drugs. The study aimed to estimate the
frequency of new AP drug use in residents newly admitted
to LTC and to explore socio-demographic and clinical fac-
tors associated with such use.
Methods
Data source
Data for the study were obtained from provincial reposi-
tories at the University of Waterloo, Canada. In Canada,
the Canadian Institute for Health Information (CIHI) re-
ceives LTC data collected using the interRAI Nursing
Home Minimum Data Set version 2.0 (MDS 2.0) instru-
ment through its Continuing Care Reporting System
(CCRS) [27]. Ontario, with a population of more than
13,000,000 people, is Canada’s most populous province
and the first to mandate interRAI instruments in clinical
practice. CIHI ensures that reporting standards are met
and performs data quality checks for all interRAI data
submissions. After submission, unique identifiers are
created to de-identify individuals and allow for linkage
with other databases.
This study used data available for research purposes
based on existing data-sharing agreements between
CIHI, interRAI and the University of Waterloo. interRAI
is an international consortium of researchers in more
than 30 countries that strives to develop comprehensive,
standardized assessment instruments to inform care and
improve the quality of life of vulnerable persons in many
care settings (www.interrai.org). This research study and
the use of anonymized MDS 2.0 data were approved by
the University of Waterloo’s Office of Research Ethics.
The MDS 2.0 instrument contains more than 300
items to comprehensively describe resident characteris-
tics, including socio-demographic variables, clinical
characteristics, physical and cognitive status, medical
diagnoses, major health problems and symptoms,
current service use and drug use. MDS diagnostic items
have demonstrated good reliability when compared to
administrative data for common chronic conditions such
as diabetes [28]. The assessment tool contains several
standardized functional scales to assess domains such as
physical functioning, cognitive status, and overall health
status. All of these scales have been validated in nursing
home populations [29–32].
When collecting information during assessment, trained
assessors, usually nurses, verify information using several
sources, including direct observation, interviews with resi-
dents, family members and formal service providers, and
review of medical records where available. From items
embedded within the MDS 2.0, a number of clinical as-
sessment protocols (CAPs) can be generated to assist in
care planning. The CCRS data for this study included as-
sessments collected between January 2003 and December
2011 from LTC facilities in Ontario.
Sample
This retrospective longitudinal study explored new use
of AP drugs among residents newly admitted to LTC fa-
cilities in Ontario between 2003 and 2011. The sample
included 70,638 individuals who had complete MDS 2.0
assessment data at baseline and 6-month follow-up as-
sessment. Individuals were excluded if they were coma-
tose, considered to be at the end of life or had no data
collected about AP drug use. Residents with neuro-
psychiatric conditions including Tourette’s syndrome,
Huntington’s disease, schizophrenia or psychiatric disor-
ders, were excluded from the current analysis as these
diseases represent labelled indications for antipsychotic
treatments. Also, patients receiving antipsychotics for
augmentation of antidepressive therapy (FDA approved
indication) have been excluded. The detailed sample de-
scription is given in Fig. 1.
Baseline and follow up assessments provided compre-
hensive information about all necessary demographic,
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clinical and social characteristics of LTC residents, as
well as about AP drug use.
Measuring AP drug use
The MDS 2.0 instrument includes a specific item about
the use of AP drugs in the seven days prior to assess-
ment. This information is verified using multiple sources
of information including physician order sheets and drug
administration records. Based on the data collected in
this item at both baseline and follow-up assessments
(after a maximum of 180 days), residents were classified
into the following groups: non-users (those without AP
drug use at baseline and follow-up), new users (those
without AP drug use at baseline, but with AP drug use
at the follow-up), continuous users (those with AP drug
use at both baseline and follow-up), or discontinuous
users (those with AP drug use at baseline, but not at
follow-up) (see Fig. 1). For the purposes of this study,
continuous and discontinuous users were excluded from
all analyses. New users of AP drugs and a control group
of non-users of AP drugs were considered in regression
modelling.
Other measures
All data on potential correlates of AP drug use were
identified from the MDS 2.0 dataset, including calcu-
lated functional scales and CAPs. The MDS 2.0 contains
an extensive list of disease diagnosis items, allowing as-
sessors to record a number of health conditions as pri-
mary or current diagnoses. The presence of dementia
(Alzheimer’s and non-Alzheimer’s types), congestive
heart failure (CHF), diabetes (both type I and II), and
hypertension were determined from this list. Items for
other symptoms and conditions, including hearing im-
pairment, visual impairment, presence of urinary tract
infections, motor agitation, presence of delusions and
pain were also available. Depressive symptoms were
identified using both the check-box item for depression
and a score of three or more on the Depression Rating
Scale (DRS) [32]. During the assessment, information
was collected about all medications taken in the previous
seven days. The mean number of drugs taken by resi-
dents was reported. Specific items describing the use of
other psychoactive medications (antidepressants, anxio-
lytics and hypnotics) allowed these potential correlates
to be analyzed.
The Activities of Daily Living (ADL) Hierarchy scale
was used to determine the level of functional status im-
pairment [30]. The Changes in Health, End-stage disease
and Signs and Symptoms (CHESS) score provided infor-
mation about instability of the health status [31]. The
Cognitive Performance Scale (CPS) incorporates memory
impairment, level of consciousness and executive func-
tions into a composite score to assess cognitive status
Fig. 1 Summary of sample selected from long-term care and complex continuing care residents. *Excludes psychiatric disorders, schizophrenia,
Tourette’s syndrome, Huntington’s disease, and hallucinations and individuals receiving antipsychotics for augmentation of anti-depressive therapy
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[29]. In each of these scales, higher scores represent in-
creasing levels of impairment or instability [29–32]. The
proportions of residents triggering the Communication
CAP (signaling communication problems) and Delirium
CAP (signaling presence of delirium) were reported and
considered as potential correlates of AP drug use.
A number of items in the dataset provided information
about social characteristics of LTC residents. The pres-
ence of wandering, verbal or physical abuse, resistance
to care or socially inappropriate behaviour was used to
create a composite item for any behavioural problems.
The presence of any conflict with staff or family and
friends and reduced social engagement were obtained
from relevant items.
For the purposes of this study, any use of trunk, limb
or chair restraints from relevant items on the assessment
was considered for analyses. Information about whether
residents had been hospitalized or whether they visited
emergency departments (EDs) in the 90 days prior to as-
sessment was also collected from specific items.
Statistical analysis
Baseline characteristics of all residents were described
according to AP drug use; differences in these character-
istics were identified using t-tests for continuous vari-
ables and chi-square tests for categorical variables. To
examine factors associated with new AP drug use, multi-
variate logistic regression modelling was performed, with
independent variables assessed in LTC residents during
the baseline assessment used as potential correlates of
new AP drug use. As gender may act as effect modifier
in the explored relationships, all analyses were stratified
by gender. All baseline characteristics were finally in-
cluded in regression models which include most of the
covariates explored. A decision was made to include
ADL and CPS scores instead of CHESS scores in the
final models. For the final models, odds ratios (ORs)
and associated 95 % confidence intervals (CIs) together
with p-values were derived. All analyses were conducted




A total of 63,660 newly admitted nursing home residents
met the inclusion criteria. Follow-up assessments within
180 days of the admission time were included, but most
follow-ups were completed around 90 days in accord-
ance with facility protocols. At admission, 19,024 newly
admitted LTC residents (29.9 %) reported AP use and
44,636 (70.1 %) did not. Of individuals not reporting AP
use at admission, the frequency of new prescription of
AP drugs was 7.0 %. At follow-up, 13,475 residents were
continuous users, 3,132 were new users and 2,417 were
discontinuous users (see Fig. 1). Only groups of new and
non-users of APs (as a control group) were considered
for analyses.
Descriptive characteristics
Non-users of AP drugs were older than new users (pro-
portion of patients younger than 85 years was approxi-
mately 47 and 54 %, respectively). Both subgroups were
predominantly female (more than 60 %) with two out of
three being dependent in ADLs. New users were signifi-
cantly more cognitively impaired than non-users (CPS > 3
in 62.2 % and 38.7 %, respectively). Behavioural problems
were common in general, but more so in the new user
group (59.2 %) (see Table 1).
Compared to non-users, residents with new AP drug
use reported more communication problems and had
higher rates of dementia, depressive symptoms, delu-
sions, and motor agitation (see Table 1). However, preva-
lence of other comorbidities such as CHF, diabetes, and
hypertension were lower among new users compared to
non-users. Behavioural problems among new AP drug
users, and more specifically rates of conflict with staff
and family/friends, were higher than those of non-users.
Reduced social engagement, on the contrary, was lower
among the new user group.
There was no difference in restraint use between new
and non-users, but new users reported more isolation.
Health status instability (as measured by the CHESS
scores) was somewhat higher in the new user group, as
was presence of delirium. No differences were observed in
prevalence of vision or hearing impairments and the mean
number of medications used in both groups was high. The
use of other psychoactive medications (antidepressants, an-
xiolytics, or hypnotics) was high overall, but higher in the
new user group compared to non-users. Hospital stays were
more common in the non-user group, but ED visits and
urinary tract infections were comparable between groups.
Correlates of new AP drug use
Two separate models were developed to explore correlates
of new AP drug use; one for women and one for men (see
Table 2). The model for women shows that younger resi-
dents were more likely to receive AP drugs within 180 days
of admission (OR 1.39; 95 % CI 1.19 – 1.61; p < 0.0001). Se-
vere cognitive impairment (OR 1.82; 95 % CI 1.48– 2.25; p
< 0.0001), and dementia (OR 1.89; 95 % CI 1.67-2.13; p <
0.0001) were the strongest clinical correlates of new AP
drug use. Presence of delusions (OR 1.60; 95 % CI 1.18-
2.17; p = 0.002), delirium (OR 1.26; 95 % CI 1.07– 1.47; p
= 0.004), and motor agitation (OR 1.24; 95 % CI 1.08-1.44;
p = 0.003) all increased the likelihood of new use of AP
drugs. Concomitant use of other psychoactive medications
was also associated with higher likelihood of new AP drug
use (OR 1.68; 95 % CI 1.50–1.88; p < 0.0001). Depressive
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Table 1 Demographic and clinical characteristics of newly admitted residents to LTC and CCC facilities in Ontario, Canada according
to antipsychotic drug use (N = 47,768)
Characteristic Non-users New users p value*
Number of residents n = 44,636 n = 3,132
n (%) n (%)
Demographic
Age, mean (SD) 83.23 (9.5) 82.51 (8.8) <0.0001
Under 65 2,152 (4.8) 128 (4.1) <0.0001
65–74 years 3,685 (8.3) 323 (10.3)
75–84 years 15,159 (34.0) 1,231 (39.3)
85+ years 23,640 (53.0) 1,450 (46.3)
Gender
Female 30,241 (67.7) 1,902 (60.7) <0.0001
Clinical
Functional Scales and CAPS
ADL Hierarchy Scalea 0 4,457 (10.0) 230 (7.3) <0.0001
1-2 13,557 (30.4) 1,023 (32.7)
3+ 26,622 (59.6) 1,879 (60.0)
CHESSb 0 25,085 (56.1) 1,782 (56.9) 0.047
1-2 17,924 (40.1) 1,211 (38.7)
3+ 1,654 (3.7) 139 (4.4)
CPSc 0 9,392 (21.0) 242 (7.7) <0.0001
1-2 17,960 (40.2) 943 (30.1)
3+ 17,284 (38.7) 1,947 (62.2)
Communication CAP 13,819 (31.0) 1,331 (42.5) <0.0001
Delirium CAP 3,048 (6.8) 338 (10.8) <0.0001
Comorbidities
Comorbid Conditions, mean (SD) 4.66 (2.2) 4.34 (2.1) <0.0001
Any Dementia 21,541 (48.3) 2,337 (74.6) <0.0001
Congestive Heart Failure 6,538 (14.7) 342 (10.9) <0.0001
Hypertension 25,770 (57.7) 1,691 (54.0) <0.0001
Diabetes (type I and/or II) 11,064 (24.8) 658 (21.0) <0.0001
Other Clinical Symptoms
Hearing Impairment 16,809 (37.7) 1,152 (36.8) 0.33
Vision Impairment 17,910 (40.1) 1,227 (39.2) 0.30
Paind 20,355 (45.6) 1,116 (35.6) <0.0001
Motor Agitation 3,172 (7.1) 445 (14.2) <0.0001
Delusions 418 (0.9) 82 (2.6) <0.0001
Depressive symptomse 8,111 (18.2) 599 (19.1) <0.0001
Urinary Tract Infection 3,315 (7.4) 213 (6.8) 0.20
Medication Use
Number of Medications, mean (SD) 9.44 (4.8) 8.48 (4.7) <0.0001
Other Psychoactive Medicationsf 20,932 (46.9) 1,611 (51.4) <0.0001
Social
Any Behavioural problemg 14,416 (32.3) 1,853 (59.2) <0.0001
Conflict with Staff 1,409 (3.2) 168 (5.4) <0.0001
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symptoms were associated with lower likelihood of new
AP use (OR 0.73; 95 % CI 0.64–0.82; <0.0001). Social fac-
tors were also found to be strong correlates of new AP
drug use. Compared to non-users with similar characteris-
tics, women who became new users were nearly twice as
likely to exhibit any behaviour problem (OR 1.91; 95 % CI
1.71–2.12; p < 0.0001). Also, conflicts with staff and fam-
ily/friends (OR 1.61; 95 % CI 1.29–2.01; p < 0.0001 and
OR 1.34; 95 % CI 1.10–1.63; p = 0.003; respectively) in-
creased the likelihood of new AP drug use, while re-
duced social engagement was associated with lower
risk (OR 0.78; 95 % CI 0.71–0.87; p < 0.0001). Having
pain or visual impairment reduced the likelihood of
new AP drug use (OR 0.89; 95 % CI 0.84–0.95; p =
0.0007 and OR 0.86; 95 % CI 0.78–0.95; p = 0.003,
respectively).
In general, the model for men is similar to the one for
women. Unlike among women, age and delirium were
not significant correlates of new AP use. Cognitive im-
pairment (OR 2.27; 95 % CI 1.74–2.97; p < 0.0001), de-
mentia (OR 2.23; 95 % CI 1.91–2.59; p < 0.0001) and any
behavioural problem (OR 2.15; 95 % CI 1.88–2.47; p <
0.0001) were all strong correlates of new AP drug use, and
these effects were stronger among men than women. The
same trend was shown for delusions (OR 1.88; 95 % CI
1.21–2.93; p = 0.005) and motor agitation (OR 1.45; 95 %
CI 1.21–1.74; p < 0.0001). Similar to women, use of other
psychoactive medications was associated with higher
likelihood of new AP drug use (OR 1.66; 95 % CI 1.44–
1.92; p < 0.0001), while depressive symptoms were associ-
ated with lower likelihood (OR 0.57; 95 % CI 0.47, 0.69).
Conflict with family and friends (OR 1.44; 95 % CI 1.10–
1.87; p = 0.008), but not with staff, was also positively asso-
ciated with new AP drug use. Hearing (OR 0.83; 95 % CI
0.73–0.94; p = 0.004), but not vision impairment, was as-
sociated with reduced likelihood of new AP drug use in
men as was the occurrence of pain (OR 0.91; 95 % CI
0.83–0.99; p = 0.03). ED visits were also significant corre-
lates of new AP drug use (OR 1.24; 95 % CI 1.02–1.50; p =
0.03), but previous hospital stays were not.
Discussion
In this large cohort of newly admitted nursing home res-
idents, 7 % became new AP drug users in the six months
following admission. This work has built upon previous
findings by identifying characteristics associated with
new AP drug use, with some interesting results. Com-
mon correlates were identified for both men and
women, for example, the presence of dementia and cog-
nitive impairment being significantly associated with
new use of AP drugs. However, other triggers were also
identified. The comprehensiveness of the MDS 2.0 data
allowed for the possibility to analyze a substantial num-
ber of novel potential correlates, setting this study apart
from earlier work. Importantly, this work also found that
behavioural and social factors, such as behavioural prob-
lems and conflicts with both staff and family and friends,
were as strongly correlated with new AP drug use as
clinical factors.
The overall rate of AP drug use in this study was
26.1 % for new and continuous users combined. Since
this rate excludes individuals with psychiatric conditions,
Table 1 Demographic and clinical characteristics of newly admitted residents to LTC and CCC facilities in Ontario, Canada according
to antipsychotic drug use (N = 47,768) (Continued)
Conflict with Family/Friends 1,863 (4.2) 223 (7.1) <0.0001
Reduced Social Engagement 27,618 (61.9) 1,620 (51.7) <0.0001
Isolation 1,468 (3.3) 131 (4.2) 0.007
Treatments and Service Use
Use of restraints 2,916 (6.5) 224 (7.2) 0.18
Hospital Stay 12,626 (28.3) 800 (25.5) 0.001
Emergency Department visits 6,752 (15.1) 461 (14.7) 0.54
Other
Days between assessments (baseline to follow up) mean (SD) 85.48 (15.6) 85.74 (15.4) 0.002
CAP, Clinical Assessment Protocol; CCC, Complex Continuing Care; LTC, Long-Term Care; SD, Standard Deviation
aADL Hierarchy Scale: Activities of Daily Living Scale [range 0-6]: Functionally independent (ADL score of 0); supervision required to limited impairment (ADL score
of 1-2); extensive impairment to total dependence (ADL score 3+)
bCHESS: Changes in Health, End-stage disease and Signs and Symptoms [range 0-6]: Health stability classified as having no health instability (CHESS score of 0);
minimal to low health instability (CHESS score of 1–2); or moderate to very high health instability (CHESS score 3+)
cCPS: Cognitive Performance Scale (CPS version 2) [range 0–6]: Intact cognition (CPS score of 0); borderline intact to mild cognitive impairment (CPS score 1–2);
moderate to very severe cognitive impairment (CPS score 3+)
dPain Scale: [range 0-4]: Pain classified as any pain (score of 1+)
eDepressive symptoms: either presence of depression using the check-box item on the MDS 2.0 or a score of 3 or more on the Depression Rating Scale
[range 0-6], which represents probable depressive symptoms
fOther Psychoactive Medication includes anti-depressants, hypnotics, or anxiolytics
gAny behavioural problems: Composite item for any wandering, verbal or physical abuse, resistance to care or socially inappropriate behaviour
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Table 2 Correlates of new antipsychotic drug use among newly admitted residents to LTC and CCC facilities in Ontario, Canada
(N = 47,768) – multivariate logistic regression models
Model for women (N = 32,143) Model for men (N = 15,625)
New users n = 1,902 New users n = 1,230
Non-users n = 30,241 Non-users n = 14,395
Characteristics Odds ratio 95 % CI p value Odds ratio 95 % CI p value
Demographic
Age (under 75 years) 1.39 (1.19, 1.61) <0.0001 1.03 (0.88, 1.22) 0.70
Clinical
ADLa score 1–2 1.03 (0.85, 1.25) 0.33 1.08 (0.84, 1.39) 0.21
ADL score 3+ 0.94 (0.78, 1.13) 0.20 0.95 (0.74, 1.22) 0.26
CPSb score 1–2 1.37 (1.13, 1.66) 0.81 1.47 (1.14, 1.89) 0.74
CPS score 3+ 1.82 (1.48, 2.25) <0.0001 2.27 (1.74, 2.97) <0.0001
Communication CAP 1.05 (0.95, 1.17) 0.34 1.04 (0.91, 1.19) 0.57
Delirium CAP 1.26 (1.07, 1.47) 0.004 1.20 (0.99, 1.47) 0.07
Any Dementia 1.89 (1.67, 2.13) <0.0001 2.23 (1.91, 2.59) <0.0001
Congestive Heart Failure 0.90 (0.77, 1.05) 0.19 0.97 (0.80, 1.17) 0.73
Hypertension 1.03 (0.93, 1.14) 0.55 0.92 (0.81, 1.04) 0.20
Diabetes (type I and/or II) 0.90 (0.80, 1.02) 0.10 0.93 (0.80, 1.07) 0.32
Hearing Impairment 1.01 (0.91, 1.11) 0.93 0.83 (0.73, 0.94) 0.004
Vision Impairment 0.86 (0.78, 0.95) 0.003 0.95 (0.84, 1.08) 0.46
Painc 0.89 (0.84, 0.95) 0.0007 0.91 (0.83, 0.99) 0.03
Motor Agitation 1.24 (1.08, 1.44) 0.003 1.45 (1.21, 1.74) <0.0001
Delusions 1.60 (1.18, 2.17) 0.002 1.88 (1.21, 2.93) 0.005
Depressive symptomsd 0.73 (0.64, 0.82) <0.0001 0.57 (0.47, 0.69) <0.0001
Urinary Tract Infection 0.99 (0.83, 1.18) 0.88 0.98 (0.89, 1.08) 0.68
Number of Medications 0.94 (0.88, 1.01) 0.11 0.95 (0.72, 1.25) 0.70
Other Psychoactive Medications e 1.68 (1.50, 1.88) <0.0001 1.66 (1.44, 1.92) <0.0001
Social
Any Behavioural Problemsf 1.91 (1.71, 2.12) <0.0001 2.15 (1.88, 2.47) <0.0001
Conflict with Staff 1.61 (1.29, 2.01) <0.0001 0.98 (0.72, 1.34) 0.90
Conflict with Family/Friends 1.34 (1.10, 1.63) 0.003 1.44 (1.10, 1.87) 0.008
Reduced Social Engagement 0.78 (0.71, 0.87) <0.0001 0.94 (0.83, 1.06) 0.32
Isolation 0.88 (0.68, 1.15) 0.35 1.11 (0.85, 1.46) 0.45
Treatments and Service Use
Use of Restraints 0.84 (0.69, 1.02) 0.07 0.85 (0.67, 1.07) 0.17
Hospital Stay 1.05 (0.93, 1.19) 0.44 0.87 (0.74, 1.02) 0.09
Emergency Department Visits 0.98 (0.84, 1.15) 0.79 1.24 (1.02, 1.50) 0.03
Other
Days between Assessments 1.00 (0.99, 1.00) 0.80 1.00 (1.00, 1.00) 0.70
CAP, Clinical Assessment Protocol; CI, confidence interval
aADL: Activities of Daily Living hierarchy scale score – reference = 0
bCPS: Cognitive Performance Scale – reference = 0
cReference = no pain on the Pain Scale
dScore of 3 or higher on the Depression Rating Scale versus score of 0
eIncludes anti-depressants, hypnotics, and anxiolytics
fPresence of any wandering, verbal or physical abuse, resistance to care or socially inappropriate behaviour
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it likely underestimates the actual rates of AP use in
these facilities. Nonetheless, it is comparable to other
Canadian and American studies [15–17]. In one Canadian
study which aimed to identify the variability of prevalence
of AP drug use in LTC settings, the overall rate of AP drug
prescribing was 32.4 % [17]. Another American study in
LTC facilities estimated a mean of 30 % residents receiving
at least one AP medication [15]. A study by Gellad and
colleagues showed an overall rate of 25.7 % of AP drug
use among long-stay nursing home residents [16]. These
rates of AP drug use are all higher than those reported in
studies from LTC settings in the United Kingdom and
Northern Ireland, which reported prevalence rates of AP
drug use of 21 % and 20.3 %, respectively [18, 26]. Thus, it
would seem that the current findings are in agreement
with current Canadian studies even though the data used
were not census-level.
Recent work by Maguire and colleagues has explored
new use of AP drugs in the period of transition from
community to institutional settings, showing that AP
drug use increased during this transition time, likely
reflecting institutional prescribing cultures [26]. How-
ever, the rate of new AP use reported in this study was
16.9 % within the six month period after admission [26].
While the current study found a much lower rate (7 %),
it may be because AP drug use is more pervasive in both
community and institutional settings in the North
American context or alternately, that shorter-term AP
use was not captured between assessments.
While it was not the purpose of this paper to explore
the appropriateness of new AP prescribing in this sam-
ple, the exclusion criteria were chosen to exclude indi-
viduals with a clear indication for AP drug use. Also,
dementia was found to be associated with an increased
likelihood of new AP drug use, but both the FDA and
EMA have issued official warnings to limit such use
[33, 34]. Interestingly, individuals receiving other psy-
choactive medications were more likely to begin to use
AP drugs, signaling a clustered prescribing pattern.
Thus, these findings may give also some insight into
the actual patterns of prescribing in institutional set-
tings. This work has many important implications for
both practice and public health policy. Findings of this
study suggest the presence of temporary indications of
AP drug prescription among newly admitted residents,
such as cognitive impairment, BPSD and delirium. In
particular, as the use of AP drugs is studied at an im-
portant point of transition in care (admission to LTC),
there may be a greater potential for interventions
based on these findings.
To date, no work has focused on correlates of new use
of AP drugs at the time of admission. The current find-
ings, that behavioural and social factors, as well as clinical
factors significantly influence new prescription of AP
drugs after LTC admission, are novel. These correlates can
act as signals to identify individuals at risk of potentially
inappropriate AP drug prescription upon LTC admission,
providing a method for targeting interventions to reduce
the potential misuse of AP drugs. Previous work has
found that higher AP drug use is linked to staff distress
and lower staff-to-patient ratios [35], but these factors
could not be explored in the current study.
There are a number of important implications from this
work. Firstly, these medications appear to be prescribed
more frequently in individuals with dementia, likely to
control associated BPSD. Such prescribing should be
closely examined, as warnings against the misuse of AP
drugs in this indication have been issued by both the FDA
and EMA [33, 34]. Further, different national guidelines
including those issued by National Institute for Health
and Care Excellence stated that these medications should
be used maximally for 6 to 12 weeks to treat behavioural
symptoms [36]. This study could not explore whether
medications were discontinued after 6 or 12 month pe-
riods. Nonetheless, it will be important follow up work to
determine methods to reduce prescribing and promote
appropriate review of AP drugs as recommended.
From a geriatric care perspective, these findings indi-
cate that AP drugs may be used to manage behaviours
or cognitive changes such as delusions. Some re-
searchers have suggested that institutional settings
should provide better mental health care [26] and these
findings support this viewpoint. Other modalities for
treating mental health issues in this cohort, such as psy-
chosocial and psychotherapeutic interventions should be
explored [1, 8]. Finally, this study focuses on a key tran-
sition period – the entry to institutional care. This tran-
sition time represents a key window of opportunity for
medication reviews, new assessments, monitoring and
follow-up. It is possible that medication review at this
time led to appropriate new AP use, as people entering
institutional environments may be particularly amenable
to improvements in their care. However, it is also pos-
sible that this new use was not appropriate. This work
has helped to identify a population potentially at risk for
inappropriate care (namely AP drug use) and a prime
target group for interventions.
A number of limitations to this study should be men-
tioned. Firstly, the sample was a convenience sample
from facilities in Ontario that use the MDS 2.0. Thus,
data are not census-level and there is the chance of se-
lection bias towards facilities that are most motivated to
comprehensively assess and manage residents. However,
rates of AP drug use reported here align with earlier
Canadian estimates [15, 17]. Next, it is possible that in-
dividuals may be prescribed AP drugs immediately upon
entry to the facility, meaning they could be counted as
continuous rather than new users. This would
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underestimate the new AP prescription rate and possible
reduce the magnitude of the associations observed. Fur-
ther, medication data were limited to those available
from the Canadian MDS 2.0 instrument. Only AP drug
use and use of hypnotics, antidepressants and anxiolytics
in the past seven days are recorded and information
about adherence is not captured. However, given that
this study was done in institutional environments, it
may be reasonable to expect high adherence rates. These
data limitations meant that it was not possible to explore
medication use between assessments or to verify that
new AP drug use is sustained, and thus the duration of
treatment was not explored. The dataset did not allow
in-depth exploration of AP drug use, specific ingredients
or whether such use was on regular or as-needed (PRN)
basis. Thus it was not possible to distinguish between
different types of AP drugs and their association with
prescription risk factors. There was no information avail-
able about facility characteristics such as the number of
beds or staffing rates and these correlates could not be
explored. This would be worthwhile future work. Finally,
it was not the aim of this study to explore potential
changes in practice towards AP use following changes in
policy, for example, the FDA warning in 2008. The sam-
ple size in the current study would not permit such
comparisons to be made, but this would be another area
that would be important for future work.
Some of the strengths of this study included the large
sample size and the comprehensiveness of the data source.
Even with lower rates of new AP drugs prescription, the
sample size was large enough to allow exploration of cor-
relates of AP drug use. Further, with the MDS 2.0 data,
this study explored a number of important potential cor-
relates including behavioural and social factors that are
not often available from administrative data sets. Finally,
by using a narrow window of transition, risk factors for
new AP drug use at an important transition time were
identified, making targeted interventions possible.
Conclusions
Overall, this work has shown that in addition to clinical
factors, behaviours and social characteristics were strongly
associated with new AP drug use upon admission to insti-
tutional care. Such knowledge can provide a first insight
into prescribing practices within nursing home environ-
ments and identify targets for interventions to increase
the quality of care afforded to older people. Reducing
inappropriate use of APs and other psychotropic medica-
tions is a goal for all facilities and this work has character-
ized a particularly vulnerable sub-population of new
residents at a higher risk of new AP prescription. Inter-
ventions to improve care for these subpopulations and im-
prove the overall mental health care in institutional
settings can utilize such information to further increase
the quality of care.
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